Rondo Therapeutics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (NCT07218003) | Rondo Therapeutics | 2025-11-17 |
Track Rondo Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.